National Institutes of Health: Neoplasms trials

The registry lists 377 Neoplasms studies with National Institutes of Health as lead sponsor. 36 are open to participants now and 81 have results posted.

Early Phase 1 3Phase 1 197Phase 2 99Phase 3 4Phase 4 1No phase 96(a study in two phases counts in both)

Studies

Page 2 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerTerminatedNCT00670748Phase 2Results posted
• Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedNCT00514046Phase 1/2Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryTerminatedNCT00482625Phase 2Results posted
• Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by SurgeryTerminatedNCT00478140Phase 2Results posted
• Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT00445549Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid CancerCompletedNCT00390325Phase 2Results posted
• Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial NeoplasiaCompletedNCT00303823Phase 2Results posted
• Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential TumorsCompletedNCT00301756Phase 2Results posted
• Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung CancerTerminatedNCT00096265Phase 3Results posted
• Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow MalignanciesCompletedNCT00079391Phase 2Results posted
• Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical CancerCompletedNCT00069160Phase 2Results posted
• Vaccine and Chemotherapy for Previously Untreated Metastatic Breast CancerTerminatedNCT00048893Phase 1/2Results posted
• Diabetes Prevention Program Outcomes StudyCompletedNCT00038727Phase 3Results posted
• EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV InfectionCompletedNCT00006436Phase 2Results posted
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and ChemotherapyCompletedNCT00004547Phase 2Results posted
• Stem Cell Transplantation for Metastatic Solid TumorsTerminatedNCT00001880Phase 2Results posted
• Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced CancerWithdrawnNCT07484282
• Experience and Management of Cancer Screening-Related Anxiety in Fanconi AnemiaActive, not recruitingNCT06744283
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnNCT06161558Phase 1
• A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) RecipientsCompletedNCT05909202Not applicable
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 2
• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingNCT05256225Phase 3
• Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedNCT04847466Phase 2
• Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)CompletedNCT04774289
• NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 DataActive, not recruitingNCT04750915
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)sTerminatedNCT04488263
• Mobile Sensor Technologies to Assess General Symptomology of People With CancerCompletedNCT04465214
• Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor PainCompletedNCT04442425
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial NeoplasiaWithdrawnNCT04411134Phase 1
• M7824 Related Adverse Effects in Adults With CancerActive, not recruitingNCT04267861
• A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerActive, not recruitingNCT04092270Phase 1
• Patient-Centered Assessment of Symptoms and OutcomesCompletedNCT03952624
• Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and LymphomasWithdrawnNCT03925428Phase 1
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionWithdrawnNCT03217253Phase 1
• Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsTerminatedNCT03189108
• The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk TradeoffsWithdrawnNCT02874053
• Natural History of and Specimen Banking for People With Tumors of the Central Nervous SystemCompletedNCT02851706
• Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary MetastasectomyWithdrawnNCT02839694Phase 1
• Collection of Tissue Blocks or Slides From Patients With CancerCompletedNCT02810405
• Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear TestCompletedNCT02734303
• Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer PatientsTerminatedNCT02706652
• Biomarker Analysis of Central Nervous System TumorsTerminatedNCT02692898
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid TumorsCompletedNCT02423057Phase 1
• Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial DistressCompletedNCT02423031
• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System TumorsCompletedNCT02415153Phase 1
• Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid TumorsCompletedNCT02379416Phase 1
• Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced CancerCompletedNCT02317874Phase 1
• Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to TreatmentActive, not recruitingNCT02243592
• Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid TumorsCompletedNCT02211755Phase 1
• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With CancerCompletedNCT02108028
• Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic DysfunctionCompletedNCT02070549Phase 1
• Study of New Software Used During AblationsCompletedNCT01906021Not applicable
• Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic NeoplasmsTerminatedNCT01862718Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• 18F-CP18 Imaging Studies for Cancer Treatment With BirinapantWithdrawnNCT01766622Phase 2
• GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnNCT01679743Phase 2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Developing the Family Map: Looking at Communal CopingCompletedNCT01633021
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
• Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System TumorsCompletedNCT01538095Phase 1
• FdCyd and THU for Advanced Solid TumorsCompletedNCT01534598Phase 1
• Family Genetics Health Education and Healthy BehaviorsCompletedNCT01498276
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerTerminatedNCT01457131Phase 1
• Dasatinib in Combination With Bevacizumab to Treat Advanced Solid TumorsCompletedNCT01445509Phase 1
• Neuropsychological Changes in Patients Receiving Radiation Therapy for Brain MetastasesCompletedNCT01445483
• A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid TumorsCompletedNCT01445106Phase 1
• NHS-IL12 for Solid TumorsCompletedNCT01417546Phase 1
• Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor RemovalTerminatedNCT01341496Phase 1
• Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting BeadsTerminatedNCT01336985Phase 1
• Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or MediastinumTerminatedNCT01313429Phase 1
• AZD6244 With Cetuximab for Solid Tumors and Colorectal CancerCompletedNCT01287130Phase 1
• Gulf Long-Term Follow-Up StudyActive, not recruitingNCT01287000
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain TumorsCompletedNCT01259479Phase 1
• AT13387 in Adults With Refractory Solid TumorsCompletedNCT01246102Phase 1
• Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid TumorsCompletedNCT01240538Phase 1
• A Comparison of Methods for Assisting Needle Angle Selection During Image-guided Tissue BiopsyCompletedNCT01218854Phase 1
• 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid TumorsCompletedNCT01191216Phase 1
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1
• Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA DamageCompletedNCT01143519
• Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT01141244Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid TumorsWithdrawnNCT01130623Phase 1
• Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma MultiformeTerminatedNCT01122888Phase 1
• Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaTerminatedNCT01088763Phase 1
• Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsCompletedNCT01076530Phase 1
• Selumetinib and Cixutumumab in Treating Patients With Advanced Solid MalignanciesCompletedNCT01061749Phase 1
• A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and LymphomasCompletedNCT01051635Phase 1
• Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum TherapyCompletedNCT01039155Phase 1
• Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaCompletedNCT00994500Phase 1
• ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCompletedNCT00946335Phase 1
• Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to TreatmentCompletedNCT00929903Phase 1